- Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
ARN-509: a novel antiandrogen for prostate cancer treatment.
Times cited: 222